LU92058I2 - Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®) - Google Patents

Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)

Info

Publication number
LU92058I2
LU92058I2 LU92058C LU92058C LU92058I2 LU 92058 I2 LU92058 I2 LU 92058I2 LU 92058 C LU92058 C LU 92058C LU 92058 C LU92058 C LU 92058C LU 92058 I2 LU92058 I2 LU 92058I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
acceptable salts
travatan
travoprost
disclosed
Prior art date
Application number
LU92058C
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92058(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of LU92058I2 publication Critical patent/LU92058I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
LU92058C 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®) LU92058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/101,598 US5510383A (en) 1993-08-03 1993-08-03 Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
EP04077870.6A EP1514548B1 (fr) 1993-08-03 1994-08-03 Composition topique ophthalmique comprenant du fluprostenol pour le traitement du glaucome et de l' hypertension intraoculaire
EP94305752.1A EP0639563B2 (fr) 1993-08-03 1994-08-03 Utilisation de l' ester isopropylique de fluprostenol pour la fabrication d'un médicament pour le traitement du glaucome et de l'hypertension oculaire

Publications (1)

Publication Number Publication Date
LU92058I2 true LU92058I2 (fr) 2012-10-08

Family

ID=22285486

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
LU92509C LU92509I2 (fr) 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92509C LU92509I2 (fr) 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)

Country Status (13)

Country Link
US (3) US5510383A (fr)
EP (3) EP1514548B1 (fr)
JP (2) JP2791544B2 (fr)
AT (1) ATE286880T2 (fr)
AU (2) AU690120B2 (fr)
CA (1) CA2129287C (fr)
DE (1) DE69434228T2 (fr)
DK (3) DK1920764T4 (fr)
ES (3) ES2458493T3 (fr)
HK (2) HK1010717A1 (fr)
LU (2) LU92058I2 (fr)
PT (3) PT1920764E (fr)
SI (3) SI1514548T1 (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
WO1997023225A1 (fr) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinaisons de prostaglandines de type dp et fp destinees a abaisser la pression intraoculaire
EP0930296B2 (fr) * 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Derives de prostaglandine fluores et medicaments
EP0948333A1 (fr) * 1996-11-01 1999-10-13 Alcon Laboratories, Inc. Utilisation d'une combinaison d'inhibiteurs d'anhydrase carbonique et de prostaglandines dans le traitement du glaucome
ES2159889T3 (es) 1996-11-12 2001-10-16 Alcon Lab Inc 15-fluoro prostaglandinas utilizadas como hipotensores oculares.
WO1998020880A2 (fr) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandines destinees au traitement du glaucome ou de l'hypertension oculaire
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
WO1999012898A1 (fr) * 1997-09-09 1999-03-18 The Procter & Gamble Company Prostaglandines tetrahydro a substitution aromatique c16-c20, utiles comme agonistes de prostaglandine f
JP2001515882A (ja) * 1997-09-09 2001-09-25 ザ プロクター アンド ギャンブル カンパニー Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
KR20010108316A (ko) 1999-03-05 2001-12-07 데이비드 엠 모이어 Ｃ16 불포화된 ｆｐ-선택적 프로스타글란딘 유사체
US6294679B1 (en) * 1999-04-12 2001-09-25 Chirotech Technology Limited Intermediate for the synthesis of prostaglandins
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
GB9908326D0 (en) * 1999-04-12 1999-06-09 Chirotech Technology Ltd Novel process intermediate for the synthesis of prostaglandins
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
EP1261598A1 (fr) * 2000-02-01 2002-12-04 Cayman Chemical Company, Inc. 1,15-lactones internes de fluprostenol et analogues de prostaglandine f2alpha apparentes, et leur utilisation dans le traitement du glaucome et de l'hypertension intraoculaire
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004098807A1 (fr) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Procede de fabrication de coupleurs en acier permettant d'assembler des barres d'armature du beton
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20050171054A1 (en) * 2001-01-19 2005-08-04 Helge Rask-Andersen Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
GB0112699D0 (en) * 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
JP2004532887A (ja) * 2001-06-01 2004-10-28 アルコン，インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
CA2447479A1 (fr) * 2001-06-01 2002-12-12 Alcon, Inc. Nouveaux analogues d'arylaminopropane et leur utilisation dans le traitement du glaucome
DE60209486T2 (de) * 2001-06-01 2006-08-03 Alcon Inc. Pyranoindazole und ihre verwendung in der glaukombehandlung
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
DE60326226D1 (de) * 2002-03-21 2009-04-02 Cayman Chemical Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
CA2488001C (fr) 2002-06-06 2011-03-22 Merck Frosst Canada & Co. Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
JP2006504679A (ja) * 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
ES2382733T3 (es) * 2002-08-29 2012-06-13 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas
CN1678302A (zh) * 2002-08-30 2005-10-05 爱尔康公司 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
CA2505127A1 (fr) * 2002-11-08 2004-05-27 James B. Doherty Compositions ophtalmiques pour traiter l'hypertension oculaire
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20070088045A1 (en) * 2002-11-12 2007-04-19 Hellberg Peggy E Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
ES2444841T3 (es) 2002-11-18 2014-02-27 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CA2506204A1 (fr) * 2002-12-13 2004-07-01 Alcon, Inc. Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
EP1646614A4 (fr) * 2003-07-01 2008-09-10 Merck & Co Inc Compositions ophtalmiques destinees au traitement d'hypertension oculaire
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
CN1845914A (zh) * 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) * 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20070093507A1 (en) * 2003-09-05 2007-04-26 Lambrou George N Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
PL1681059T3 (pl) 2003-11-07 2010-01-29 Senju Pharma Co Kompozycja farmaceutyczna zawierająca prostaglandynę
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) * 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) * 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005079809A1 (fr) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Gouttes pour les yeux transparentes au latanoprost
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
PL1740164T3 (pl) * 2004-04-26 2009-01-30 Alcon Inc Statyny do leczenia nadciśnienia śródgałkowego i jaskry
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
AU2005295997A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2583622A1 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Compositions ophtalmiques de traitement de l'hypertension oculaire
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US7425572B2 (en) * 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
JP5060311B2 (ja) * 2005-01-14 2012-10-31 アラーガン インコーポレイテッド 高眼圧症状を処置するための置換シクロペンタンまたはシクロペンタノン
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (fr) 2009-03-04 2010-09-10 Allergan, Inc. Solution ophtalmique améliorée à base de bimatoprost
SI1864666T1 (sl) 2005-03-31 2012-10-30 Asahi Glass Co Ltd Zaščitno sredstvo za retinalno nevronsko celico, vsebujoče derivat prostaglandina F2 alfa kot učinkovino
US8252945B2 (en) 2005-04-13 2012-08-28 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
US20090270395A1 (en) * 2005-08-03 2009-10-29 John Colucci EP4 Receptor Agonist, Compositions and Methods Thereof
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1810967B1 (fr) 2006-01-18 2014-07-30 Chirogate International Inc. Procédé et produits intérmediaires pour la fabrication de prostaglandines
WO2007091970A1 (fr) * 2006-02-06 2007-08-16 Synphora Ab Nouvelles méthode et compositions pour traiter un acouphène
EP1994933B1 (fr) * 2006-03-13 2017-04-26 R-Tech Ueno, Ltd. Composition aqueuse
WO2007108968A2 (fr) * 2006-03-13 2007-09-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
WO2007111806A2 (fr) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Compositions et procedes pour la reduction des tissus adipeux de l'organisme
AU2007258527A1 (en) * 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
EP2291346A2 (fr) * 2008-05-15 2011-03-09 Allergan, Inc. Cyclopentanes substitués à visée thérapeutique
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010112615A1 (fr) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Dérivés de lysine fonctionnalisés avec des lipides
CA2760562C (fr) 2009-05-01 2016-07-19 Aerie Pharmaceuticals, Inc. Inhibiteurs a mecanisme double pour le traitement de maladie
EP2478906A4 (fr) 2009-09-17 2013-02-20 Senju Pharma Co Gouttes ophtalmiques aqueuses qui contiennent du latanoprost, et procédé d'inhibition de l'adsorption du latanoprost sur une résine
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
BR112013002584A2 (pt) 2010-08-02 2016-06-07 Pharma Patent Holding Inc composição, processo de kit para aperfeiçoamento de cabelo
EP3178465A1 (fr) 2010-12-06 2017-06-14 Follica, Inc. Procédé de traitement de calvitie et favorisant la pousse des cheveux
ES2687494T3 (es) 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
TW201906614A (zh) 2011-02-04 2019-02-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之點眼藥
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
US20150031898A1 (en) * 2012-03-09 2015-01-29 Instytut Farmaceutyczny Process for preparation of prostaglandin f2 alpha analogues
SG11201600237YA (en) 2012-11-21 2016-02-26 Topokine Therapeutics Inc Methods and compositions for locally increasing body fat
HU230744B1 (hu) 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
CA2905089C (fr) 2013-03-15 2023-06-13 Aerie Pharmaceuticals, Inc. Compose d'isoquinoline pour traiter des maladies oculaires
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3091985B1 (fr) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandines pour leur utilisation topique dans le traitement des migraines.
HU231214B1 (hu) 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
WO2015200425A1 (fr) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Forme posologique à usage topique
AU2015332447B2 (en) * 2014-10-15 2018-10-25 Alcon Inc. Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension
US11285163B2 (en) 2014-10-20 2022-03-29 Sentiss Pharma Private Limited Ophthalmic solution
JP6686023B2 (ja) 2014-11-25 2020-04-22 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法
WO2016155906A1 (fr) 2015-03-31 2016-10-06 Nicox S.A. Dérivés de fluprosténol donneurs d'oxyde nitrique
CA2999988C (fr) 2015-09-27 2024-06-11 Follica, Inc. Dispositif de piqure et applicateur de medicament
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
EP3609871A4 (fr) 2017-03-31 2021-01-06 Aerie Pharmaceuticals, Inc. Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350971A (en) * 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
GB1486832A (en) * 1974-08-05 1977-09-28 Ici Ltd Prostanoic acid derivatives
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4159343A (en) * 1975-05-26 1979-06-26 Schering Aktiengesellschaft Prostane derivatives
DE2523676A1 (de) * 1975-05-26 1976-12-16 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
DE03014533T1 (de) * 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
EP0580268B1 (fr) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Agents oculaires hypotenseurs
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
HU212570B (en) † 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
SI0639563T1 (en) 2005-06-30
DK1920764T4 (da) 2020-03-16
ES2235158T3 (es) 2005-07-01
ES2235158T5 (es) 2016-05-25
PT1514548E (pt) 2014-04-22
JP3650258B2 (ja) 2005-05-18
EP1920764B2 (fr) 2020-01-08
DK1920764T3 (da) 2012-07-02
LU92509I2 (fr) 2015-10-21
DK1514548T3 (da) 2014-03-17
PT639563E (pt) 2005-05-31
AU690120B2 (en) 1998-04-23
ES2385267T5 (es) 2020-07-21
EP0639563A2 (fr) 1995-02-22
EP1514548A3 (fr) 2005-04-06
SI1514548T1 (sl) 2014-04-30
SI1920764T2 (sl) 2020-03-31
AU6877994A (en) 1995-02-23
JPH07165703A (ja) 1995-06-27
HK1072716A1 (en) 2005-09-09
AU7748898A (en) 1998-10-01
EP1514548A2 (fr) 2005-03-16
ES2385267T3 (es) 2012-07-20
ES2458493T8 (es) 2014-08-27
AU704670B2 (en) 1999-04-29
EP1514548B1 (fr) 2014-02-26
ES2458493T3 (es) 2014-05-05
EP0639563A3 (fr) 1996-10-16
US5510383A (en) 1996-04-23
US5889052A (en) 1999-03-30
HK1010717A1 (en) 1999-06-25
JP2791544B2 (ja) 1998-08-27
SI1920764T1 (sl) 2012-08-31
ATE286880T2 (de) 2005-01-15
EP1920764B1 (fr) 2012-05-16
DK0639563T4 (en) 2016-01-11
DE69434228D1 (de) 2005-02-17
EP0639563B2 (fr) 2015-09-30
DK0639563T3 (da) 2005-03-21
JPH10182465A (ja) 1998-07-07
PT1920764E (pt) 2012-07-20
EP1920764A1 (fr) 2008-05-14
CA2129287A1 (fr) 1995-02-04
EP0639563B1 (fr) 2005-01-12
CA2129287C (fr) 2002-05-14
DE69434228T2 (de) 2006-02-02
US5665773A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
LU92058I2 (fr) Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1995034302A3 (fr) Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium
EP0345028A3 (fr) Utilisation d'un inhibiteur de la phosphodiestérase pour le traitement du glaucome
DE69829227D1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
EP1300150A3 (fr) Dérivés de prostaglandines servant au traitement du glaucome ou de l'hypertension oculaire
IT1241928B (it) Composizione oftalmica per l'uso nel mantenimento della midriasi oculare